NUCLEIC ACID TRIGGERED DRUG & PROBE RELEASE

核酸触发药物

• 批准号: 8361329
• 负责人: JOHN-STEPHEN Adolfino TAYLOR
• 金额: $ 0.29万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361329
• 关键词: Base Sequence; Biological; Cell Death; Cells; Cessation of life; Cytotoxic agent; DNA Sequence; Disease; Drug Formulations; Funding; Genetic; Grant; Mass Spectrum Analysis; Messenger RNA; National Center for Research Resources; Nucleic Acids; Nucleic acid sequencing; Pharmaceutical Preparations; Principal Investigator; Prodrugs; Research; Research Infrastructure; Resources; Source; United States National Institutes of Health; biomedical resource; catalyst; chemotherapeutic agent; chemotherapy; cost; design

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The aim of this project is to develop a new and general approach to the design and synthesis of easily programmable, disease-specific chemotherapeutic agents and probes that make direct use of genetic information to trigger the death of a diseased cell. The idea is to make use of a disease-specific mRNA or DNA sequence to direct the association of a pro-drug and an activator capable of converting the pro-drug to an active drug. In this approach the nucleic acid is used not as a target, but as a trigger, and thus does not depend on the biological activity of the disease-specific nucleic acid sequence, only on its uniqueness and accessibility. We are investigating the feasibility of one formulation of this new concept to chemotherapy in which the pro-drug component consists of a drug attached to a segment of PNA that is complementary to one section of a disease specific mRNA, and the activating component consists of a catalyst attached to a segment of PNA that i s c omplementary to the adjoining section of the mRNA. Only in a diseased cell can the disease specific mRNA cause the two components to associate which then results in the conversion of the pro-drug to a cytotoxic drug and death of the cell.

这个子项目是利用这些资源的众多研究子项目之一